drugset / Trial / NCT02479204

Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441

NCT02479204

Phase 1 Terminated 10 enrolled Viatris Innovation GmbH
RandomizedParallel-groupOpen-labelOther

Summary

The aim of the study is to investigate the safety of the concomitant administration of ACT-334441 with cardiovascular drugs.

Timeline

Start
2015-04-28
Primary completion
2016-05-01
Completion
2016-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Atenolol Other / unclassified 50 mg
Subject Cenerimod Small molecule 2 mg
Subject Cenerimod Small molecule 4 mg
Subject Diltiazem Small molecule 240 mg

Indications

No indication recorded.